Texas Oncology and Baylor Sammons Cancer Center, Dallas.

Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was conducted to examine the efficacy and toxicities of sunitinib in metastatic CRPC progressing after 1-2 previous chemotherapy regimens including docetaxel. The primary objective was clinical progression-free survival (PFS) with a 12-week PFS >/= 30% assumed to be of interest. Secondary objectives included prostate-specific antigen (PSA) response, modulation of PSA kinetics, objective response, quality of life, pain, survival, and toxicities. Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity.

Written by:
Sonpavde G, Hutson TE, Berry WR, Boehm KA, Asmar L.   Are you the author?

Reference:
Clin Genitourin Cancer. 2008 Sep;6(2):134-7.

PubMed Abstract
PMID:18824440

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!